SAN FRANCISCO--(BUSINESS WIRE)--Glialogix, Inc, a San Francisco Bay Area-based emerging biopharma company, today announced that it has entered into a Sponsored Research Agreement with Fast Forward, a nonprofit organization established by the National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Through this agreement, Fast Forward will provide funding to Glialogix for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS. Supporting the research and development of therapies that reduce the accumulation of disability in progressive MS and restore neuronal function is a key priority of the National MS Society’s research campaign.
“The treatment of patients with progressive MS represents a significant unmet medical need. The majority of MS disability occurs in the progressive forms of MS, but drugs that are effective for relapsing MS have shown limited to no efficacy in progressive MS,” said Mark Moore, Ph.D., Chief Executive Officer of Glialogix. “The research funding from Fast Forward validates our therapeutic approach for GLX1112 and will help us advance this investigational drug as a potential breakthrough therapy for the treatment of patients with progressive MS. We look forward to working with Fast Forward’s expert staff and advisors.”
Help employers find you! Check out all the jobs and post your resume.
